Stockscreener 앱 받기
11.10
6.41%
-0.76
전일 마감가:
$11.86
열려 있는:
$12.03
하루 거래량:
1.84M
Relative Volume:
2.18
시가총액:
$1.43B
수익:
$628.25M
순이익/손실:
$-78.55M
주가수익비율:
-17.90
EPS:
-0.62
순현금흐름:
$-29.73M
1주 성능:
-23.02%
1개월 성능:
-21.72%
6개월 성능:
-32.44%
1년 성능:
-32.65%
1일 변동 폭
$10.90
$12.03
1주일 범위
$10.69
$13.30
52주 변동 폭
$10.69
$19.11
Neogenomics Inc Stock (NEO) Company Profile
명칭
Neogenomics Inc
전화
(239) 768-0600
주소
9490 NEOGENOMICS WAY, FORT MYERS, FL
NEO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
11.10 | 1.43B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
532.55 | 203.70B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.23 | 151.18B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
135.37 | 38.62B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
452.77 | 37.07B | 3.90B | 887.87M | 808.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
191.04 | 33.64B | 15.41B | 1.37B | 2.11B | 7.50 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-13 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-12-10 | 개시 | Jefferies | Buy |
| 2024-05-01 | 재개 | Craig Hallum | Buy |
| 2023-12-29 | 재확인 | BTIG Research | Buy |
| 2023-08-21 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2023-02-24 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-02-01 | 업그레이드 | Needham | Hold → Buy |
| 2022-08-26 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-08-22 | 다운그레이드 | Needham | Buy → Hold |
| 2022-06-03 | 개시 | Piper Sandler | Overweight |
| 2022-03-29 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-29 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | 재개 | Stephens | Overweight |
| 2021-12-16 | 개시 | Cowen | Outperform |
| 2021-11-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-02-25 | 재개 | Needham | Buy |
| 2021-02-25 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-12-11 | 재개 | BTIG Research | Buy |
| 2020-10-28 | 재확인 | Needham | Buy |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-08-28 | 개시 | Guggenheim | Buy |
| 2020-07-29 | 재확인 | Needham | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Buy |
| 2020-04-21 | 재개 | Stephens | Overweight |
| 2020-03-02 | 재개 | Craig Hallum | Buy |
| 2020-02-28 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | 재확인 | Needham | Buy |
| 2019-05-01 | 재확인 | Needham | Buy |
| 2019-03-29 | 재확인 | Needham | Buy |
| 2019-01-03 | 개시 | Needham | Buy |
| 2018-10-24 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | 개시 | Leerink Partners | Outperform |
| 2018-05-02 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2017-08-24 | 개시 | Gabelli & Co | Buy |
| 2016-12-15 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Neogenomics Inc 주식(NEO)의 최신 뉴스
NeoGenomics plummets on Q4 2024 bottom line miss, soft EPS guidance - MSN
Bank of America Issues Pessimistic Forecast for NeoGenomics (NASDAQ:NEO) Stock Price - MarketBeat
NeoGenomics (NASDAQ:NEO) Price Target Cut to $18.00 by Analysts at Needham & Company LLC - MarketBeat
NeoGenomics Schedules its Third Quarter 2021, Earnings Release for November 4, 2021 - ACCESS Newswire
BTIG cuts Neogenomics price target to $17, maintains Buy rating - Investing.com India
BTIG cuts Neogenomics price target to $17, maintains Buy rating By Investing.com - Investing.com Canada
NeoGenomics, Inc. (NASDAQ:NEO) Q4 2024 Earnings Call Transcript - MSN
NeoGenomics (NASDAQ:NEO) Sets New 52-Week Low After Earnings Miss - MarketBeat
Morgan Stanley cuts Neogenomics stock target to $17 from $18 By Investing.com - Investing.com Canada
NeoGenomics (NASDAQ:NEO) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat
NeoGenomics price target lowered to $19 from $20 at TD Cowen - TipRanks
NeoGenomics (NASDAQ:NEO) Issues Earnings Results - MarketBeat
NeoGenomics targets 1M patients annually by 2028 with 11%-13% revenue growth in 2025 - MSN
Demystifying NeoGenomics: Insights From 6 Analyst Reviews - Benzinga
NeoGenomics Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
NeoGenomics: Q4 Earnings Snapshot - CT Insider
NeoGenomics Inc (NEO) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Parp Inhibitor Biomarkers Market Future Business - openPR
NeoGenomics Achieves Double-Digit Revenue Growth in 2024 - TipRanks
Raymond James holds Neogenomics at Market Perform By Investing.com - Investing.com Nigeria
NeoGenomics Q4 Earnings Call Highlights Growth Amid Challenges - TipRanks
NeoGenomics Quarterly Results: Shares Plummet Amidst Financial ConcernsNews and Statistics - IndexBox, Inc.
Why NeoGenomics (NEO) Shares Are Trading Lower Today By Stock Story - Investing.com Canada
Why NeoGenomics (NEO) Shares Are Trading Lower Today - Financial Content
NeoGenomics stock tumbles on weak EPS guidance By Investing.com - Investing.com Nigeria
Trend Tracker for (NEO) - Stock Traders Daily
NeoGenomics (NEO) Tops Q4 Earnings Estimates - MSN
Earnings call transcript: NeoGenomics Q4 2024 earnings beat expectations, stock drops - Investing.com
NeoGenomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Raymond James holds Neogenomics at Market Perform - Investing.com India
Neogenomics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt - Simply Wall St
NeoGenomics reports Q4 adjusted EPS 4c, consensus 3c - TipRanks
NeoGenomics Reports Fourth Quarter and Full Year 2024 Results - BioSpace
NEOGENOMICS Earnings Results: $NEO Reports Quarterly Earnings - Nasdaq
Earnings Flash (NEO) NeoGenomics Posts Q4 Revenue $172M, vs. FactSet Est of $173.2M - Marketscreener.com
Neogenomics Inc Reaffirms Full-Year 2025 Guidance -February 18, 2025 at 07:19 am EST - Marketscreener.com
NeoGenomics (NASDAQ:NEO) Misses Q4 Sales Targets - Yahoo Finance
Not Just a DEX: How Pineapple’s Mystery Marketing is Changing the Game - GlobeNewswire Inc.
NeoGenomics (NEO) To Report Earnings Tomorrow: Here Is What To Expect - MSN
NeoGenomics Set to Surpass Revenue Growth ProjectionsNews and Statistics - IndexBox, Inc.
Brokerages Set NeoGenomics, Inc. (NASDAQ:NEO) Target Price at $20.20 - MarketBeat
NeoGenomics (NEO) Projected to Post Earnings on Tuesday - MarketBeat
NeoGenomics Q4 2024 Earnings Preview - MSN
NeoGenomics Reports 9% Revenue Growth to $116 Million in the First Quarter - ACCESS Newswire
NeoGenomics To Participate In The Stephens Annual Investment Conference 2021 - ACCESS Newswire
NeoGenomics Enters Strategic Collaboration with Inivata to Commercialize InVisionFirst(R)-Lung Liquid Biopsy Test - ACCESS Newswire
NeoGenomics Appoints David Perez, Industry Veteran and Former Terumo BCT CEO, to Its Board of Directors - ACCESS Newswire
Neogenomics Inc (NEO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.06%
3.50%
자본화:
|
볼륨(24시간):